CARD14 Signalling Ensures Cell Survival and Cancer Associated Gene Expression in Prostate Cancer Cells.
CARD14
MALT1
prostate cancer
protease
tumour cell survival
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
18 Aug 2022
18 Aug 2022
Historique:
received:
04
07
2022
revised:
10
08
2022
accepted:
11
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Prostate cancer (PCa) is one of the most common cancer types in men and represents an increasing global problem due to the modern Western lifestyle. The signalling adapter protein CARD14 is specifically expressed in epithelial cells, where it has been shown to mediate NF-κB signalling, but a role for CARD14 in carcinoma has not yet been described. By analysing existing cancer databases, we found that CARD14 overexpression strongly correlates with aggressive PCa in human patients. Moreover, we showed that CARD14 is overexpressed in the LNCaP PCa cell line and that knockdown of CARD14 severely reduces LNCaP cell survival. Similarly, knockdown of BCL10 and MALT1, which are known to form a signalling complex with CARD14, also induced LNCaP cell death. MALT1 is a paracaspase that mediates downstream signalling by acting as a scaffold, as well as a protease. Recent studies have already indicated a role for the scaffold function of MALT1 in PCa cell growth. Here, we also demonstrated constitutive MALT1 proteolytic activity in several PCa cell lines, leading to cleavage of A20 and CYLD. Inhibition of MALT1 protease activity did not affect PCa cell survival nor activation of NF-κB and JNK signalling, but reduced expression of cancer-associated genes, including the cytokine IL-6. Taken together, our results revealed a novel role for CARD14-induced signalling in regulating PCa cell survival and gene expression. The epithelial cell type-specific expression of CARD14 may offer novel opportunities for more specific therapeutic targeting approaches in PCa.
Identifiants
pubmed: 36009554
pii: biomedicines10082008
doi: 10.3390/biomedicines10082008
pmc: PMC9405774
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Research Foundation - Flanders
ID : G0I1422N
Organisme : Stichting tegen Kanker
ID : FAF-F/2016/812
Organisme : Cancer Research Institute Ghent
ID : YIPOC
Organisme : Stichting tegen Kanker
ID : Fundamental mandate 2021-021
Organisme : Ghent University
ID : BOF19/GOA/004
Références
Am J Hum Genet. 2021 Jun 3;108(6):1026-1039
pubmed: 34004138
EMBO J. 2011 May 4;30(9):1742-52
pubmed: 21448133
Cells. 2018 Aug 29;7(9):
pubmed: 30158439
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Am J Hum Genet. 2012 May 4;90(5):784-95
pubmed: 22521418
Int J Mol Sci. 2020 Jun 25;21(12):
pubmed: 32630372
Cancer Drug Resist. 2021;4:244-263
pubmed: 34337349
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Mol Med Rep. 2020 Jan;21(1):329-337
pubmed: 31939627
iScience. 2020 Sep 12;23(10):101557
pubmed: 33083726
EMBO Rep. 2016 Jun;17(6):914-27
pubmed: 27113748
Biomedicines. 2021 Mar 03;9(3):
pubmed: 33802402
Curr Opin Hematol. 2016 Jul;23(4):402-9
pubmed: 27135977
Sci Signal. 2013 Jan 08;6(257):ra3
pubmed: 23300340
J Immunol. 2018 Jan 1;200(1):71-81
pubmed: 29150564
Biomed Pharmacother. 2020 Jan;121:109679
pubmed: 31810118
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):56-61
pubmed: 22850906
Can J Urol. 2008 Feb;15(1):3866-71
pubmed: 18304396
FEBS J. 2021 Mar;288(5):1630-1647
pubmed: 32790937
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Front Immunol. 2019 Aug 14;10:1898
pubmed: 31474984
Int J Oral Sci. 2009 Sep;1(3):105-18
pubmed: 20695076
FEBS J. 2015 Sep;282(17):3286-97
pubmed: 25996250
Am J Hum Genet. 2012 May 4;90(5):796-808
pubmed: 22521419
PLoS One. 2012;7(5):e36903
pubmed: 22615840
Front Immunol. 2022 May 09;13:875320
pubmed: 35615349
Oncogene. 2016 Feb 18;35(7):919-28
pubmed: 25982276
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Front Immunol. 2020 Apr 30;11:745
pubmed: 32425939
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Trends Mol Med. 2016 Feb;22(2):135-150
pubmed: 26787500
Mol Cancer Res. 2016 Jan;14(1):93-102
pubmed: 26392569
Front Mol Biosci. 2021 Dec 02;8:714906
pubmed: 34926571
Signal Transduct Target Ther. 2019 Dec 24;4:64
pubmed: 31885879
Cell Rep. 2020 Jul 28;32(4):107959
pubmed: 32726624
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Leuk Lymphoma. 2022 Apr;63(4):789-798
pubmed: 34783281
Nat Immunol. 2008 Mar;9(3):263-71
pubmed: 18223652
Obes Rev. 2018 Jul;19(7):1008-1016
pubmed: 29573216
Oncogene. 2008 Feb 21;27(9):1273-80
pubmed: 17724468
J Cell Physiol. 2014 Aug;229(8):990-7
pubmed: 24375035
Tumour Biol. 2013 Oct;34(5):3041-7
pubmed: 23708960
Biochem J. 2016 Jun 15;473(12):1759-68
pubmed: 27071417
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Trends Genet. 2018 Jul;34(7):518-531
pubmed: 29735283
Immunol Cell Biol. 2018 Jan;96(1):81-99
pubmed: 29359407